Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Syntabio LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, which corresponds to the distinct art unit active for the company. This concentration suggests that the portfolio's current prosecution is focused on a specific pharmaceutical or biological innovation. Such a narrow scope means that the company's immediate patenting success is highly sensitive to the individual examiner's interpretation of the claims.
KIM, SEONG JONG is the busiest examiner for the portfolio, handling the pending office action. This matter constitutes the entirety of the company's pending workload. Consequently, the immediate results for the portfolio depend on the specific examination style and requirements of this examiner within the biotechnology sector. Practitioners should prioritize a thorough understanding of this examiner's previous actions to navigate the 1 pending office action effectively and secure the company's intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704873 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | KIM, SEONG JONG | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704873 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | KIM, SEONG JONG | 1621 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSyntabio LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Seong Jong Kim has the most, with 1 of Syntabio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
